However, TRPV1’s role in arthritis-related pain sensation is not without some controversy, as a study by Ängeby Möller et al. found no reduction in guarding behavior in an adjuvant-arthritis model in response to oral administration of the TRPV1 antagonist AZD1386 [68], and a study by Okun et al. found no reduction in pain behaviors as judged by a conditioned place preference assay in response to antagonism of TRPV1 with AMG9810 [69]. This evidence concerns the gene TRPV1 and arthritic joint disease.